Torrent Pharma Ltd. (BSE: 500420) is a Ahmedabad, Gujarat-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹1,70,481 Cr, it ranks #50 by market cap among the 6,189 Indian listed companies on FinBizNet, and #1 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹4,482.00 (as of 26 Oct 2026), the share price is 14.6% below its 52-week high of ₹5,250.00 and 26.9% above its 52-week low of ₹3,532.60. The share price is up 28.0% over one year and down 8.8% over three months.
| Current Price | ₹4,482.00 |
|---|---|
| Market Cap | ₹1,70,481 Cr |
| BSE Code | 500420 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 70.1 |
| Return on Equity | 16.98% |
| Return on Assets | 7.25% |
| 52-Week Range | ₹3,532.60 – ₹5,250.00 |
| 1-Year Price Change | +28.0% |
| 3-Month Price Change | -8.8% |
| Beta (1Y) | 0.32 |
| Dividend Yield | 0.40% |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.torrentpharma.com |
| Revenue | ₹4,979 Cr |
|---|---|
| Net Profit | ₹534 Cr |
| Net Margin | 10.7% |
| EPS (Basic) | ₹14.05 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, cosmo-dermatology, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Limited.
1. Generic Formulation Business-This segment engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations. It also engages in contract manufacturing business.
1. Generic Formulation Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,70,481 Cr | 70.1 | 16.98% | ₹4,979 Cr | +28.0% |
| Aether Industries Limited | ₹18,748 Cr | 85.4 | 9.81% | ₹327 Cr | +88.8% |
| Alivus Life Sciences Ltd | ₹15,350 Cr | 27.2 | 18.36% | ₹640 Cr | +33.8% |
| Aarti Pharmalabs Ltd | ₹7,443 Cr | 42.6 | 8.49% | ₹536 Cr | -4.1% |
| Solara Active Pharma Sciences Limited | ₹2,951 Cr | -363.4 | -0.63% | ₹417 Cr | +3.3% |
| Sai Parenteral's Limited | ₹2,040 Cr | 105.9 | 2.88% | ₹179 Cr | — |
| KRM Ayurveda Limited | ₹508 Cr | 25.2 | — | ₹32 Cr | — |
| Trident Lifeline Limited | ₹486 Cr | 24.9 | — | — | +39.4% |
| Infinium Pharmachem Limited | ₹446 Cr | 36.7 | — | — | +13.5% |
Listed by market capitalisation. Ratios are shown for context only.
Torrent Pharma Ltd. is trading at ₹4,482.00, with a market capitalisation of ₹1,70,481 Cr.
Torrent Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Torrent Pharma Ltd. has a P/E of 70.1 and a return on equity of 16.98%.
Torrent Pharma Ltd. is listed on the BSE under the scrip code 500420.
Torrent Pharma Ltd.'s share price is up 28.0% over one year and down 8.8% over three months. Its 52-week range is ₹3,532.60 to ₹5,250.00.
In Q2 FY27, Torrent Pharma Ltd. reported revenue of ₹4,979 Cr and net profit of ₹534 Cr, with basic EPS of ₹14.05 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.